ADMA Biologics

160 articles with ADMA Biologics

• ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update

  5/11/2022

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its first quarter 2022 financial results and provided a business update.  

• ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET

  5/4/2022

  ADMA Biologics, Inc. today announced that it will report financial results for the first quarter ended March 31, 2022 on Wednesday, May 11, 2022, after the U.S. financial markets close.

• ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022

  4/1/2022

  ADMA Biologics, Inc. announced a poster presentation and exclusive Key Opinion Leader symposium by nationally recognized clinical experts on the management of respiratory viral infections and real-world experience with ADMA’s ASCENIV, a U.S. Food and Drug Administration -approved intravenous immunoglobulin product with a unique composition.

• ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months

  3/25/2022

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the United States Food and Drug Administration’s approval to extend the expiration dating from 24 to 36 months for both its ASCENIV and BIVIGAM immune globulin drug product stored at 2-8°C.

• ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management

  3/24/2022

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2021 financial results.

• ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

  3/21/2022

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 24, 2022 after the U.S. financial markets close.

• ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA

  3/7/2022

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it has received U.S. Food and Drug Administration approval for its fifth ADMA BioCenters plasma collection facility located in Conyers, Georgia.

• ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update

  1/19/2022

  Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception.

• ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SCFDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023

  1/18/2022

  ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its fourth ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina.

• ADMA Biologics Provides Update on Global Intellectual Property Portfolio

  12/9/2021

  ADMA Biologics, Inc. today announced that the European Patent Office (EPO) has issued European Patent No. 3375789, to the Company.

• ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors

  11/17/2021

  ADMA Biologics, Inc. today announced that Cyndi Tolman, ADMA’s Senior Vice President of Plasma Services, has been elected to serve on the PPTA Source Board of Directors (“PPTA Source Board”) for the 2022 to 2024 election term.  

• ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SCADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction

  11/16/2021

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters location in Myrtle Beach, South Carolina.

• ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET

  11/3/2021

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it will report financial results for the third quarter ended September 30, 2021 on Wednesday, November 10, 2021 after the U.S. financial markets close.

• ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  10/25/2021

  ADMA Biologics, Inc. announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters’ option to purchase an additional 7.5 million shares of common stock.

• 

  BioSpace Movers & Shakers, Oct. 22

  10/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference

  10/22/2021

  ADMA Biologics, Inc. today announced that a poster presentation was made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference.

• ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock

  10/21/2021

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share.

• ADMA Biologics Announces Proposed Public Offering of Common Stock

  10/20/2021

  ADMA Biologics, Inc. today announced that it intends to offer shares of its common stock for sale in an underwritten public offering.

• ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference

  10/19/2021

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), today announced that a poster presentation will be made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference, which will take place on October 19-22.

• ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.

  10/18/2021

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors.